A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
Latest Information Update: 23 Nov 2022
At a glance
- Drugs Elismetrep (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 20 Nov 2022 Status changed from active, no longer recruiting to completed.
- 05 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 03 Dec 2021 Status changed from not yet recruiting to recruiting.